- Home
- IGMS vs TYRA Comparison
IGMS vs TYRA Comparison
Compare IGMS & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- TYRA
- Stock Information
- Founded
- IGMS 1993
- TYRA 2018
- Country
- IGMS United States
- TYRA United States
- Employees
- IGMS N/A
- TYRA N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- TYRA Health Care
- Exchange
- IGMS Nasdaq
- TYRA Nasdaq
- Market Cap
- IGMS 962.1M
- TYRA 871.8M
- IPO Year
- IGMS 2019
- TYRA 2021
- Fundamental
- Price
- IGMS $9.47
- TYRA $15.39
- Analyst Decision
- IGMS Hold
- TYRA Strong Buy
- Analyst Count
- IGMS 8
- TYRA 5
- Target Price
- IGMS $14.63
- TYRA $31.00
- AVG Volume (30 Days)
- IGMS 238.9K
- TYRA 625.3K
- Earning Date
- IGMS 11-08-2024
- TYRA 11-07-2024
- Dividend Yield
- IGMS N/A
- TYRA N/A
- EPS Growth
- IGMS N/A
- TYRA N/A
- EPS
- IGMS N/A
- TYRA N/A
- Revenue
- IGMS $2,918,000.00
- TYRA N/A
- Revenue This Year
- IGMS $298.54
- TYRA N/A
- Revenue Next Year
- IGMS N/A
- TYRA N/A
- P/E Ratio
- IGMS N/A
- TYRA N/A
- Revenue Growth
- IGMS 57.64
- TYRA N/A
- 52 Week Low
- IGMS $4.72
- TYRA $10.60
- 52 Week High
- IGMS $22.50
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- IGMS 28.30
- TYRA 32.20
- Support Level
- IGMS $10.91
- TYRA $15.74
- Resistance Level
- IGMS $16.32
- TYRA $16.68
- Average True Range (ATR)
- IGMS 1.53
- TYRA 1.30
- MACD
- IGMS -0.79
- TYRA -0.21
- Stochastic Oscillator
- IGMS 0.80
- TYRA 6.42
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).